Eprosartan
Authoritative Clinical Reference
Navigation
DRUG NAME: Eprosartan
Therapeutic Class: Antihypertensive
Subclass: Angiotensin II Receptor Blocker (ARB)
Schedule (India): Schedule H
Route(s): Oral
Formulations Available in India:
-
Tablets: 400 mg, 600 mg
ADULT INDICATIONS + DOSING
Primary Indications (Approved / Standard in India)
1. Hypertension (Essential / Primary)
| Parameter | Detail |
|
Starting dose
|
600 mg once daily |
|
Titration
|
Reassess blood pressure after 2–3 weeks; increase or split dose if target BP not achieved |
|
Usual maintenance dose
|
600 mg once daily (may be given as 400 mg + 200 mg or 300 mg twice daily in select patients, though commonly kept as a single daily dose) |
|
Maximum dose
|
800 mg per day (in one or two divided doses) |
|
Key clinical notes
|
• May be used as monotherapy or combined with a thiazide diuretic or calcium channel blocker for additive BP lowering • Onset of antihypertensive effect within 1–2 weeks; maximal effect by 2–3 weeks • Unlike most other ARBs, eprosartan is a non-biphenyl, non-tetrazole compound; it additionally blocks presynaptic angiotensin II receptors on sympathetic nerve terminals, providing a modest sympatholytic effect • Volume- or salt-depleted patients (e.g., those on high-dose diuretics or with restricted salt intake) should have volume corrected before initiation or start with a reduced dose of 400 mg daily • No dose adjustment needed based on gender or age alone, but clinical caution in the elderly (see Elderly section) • If switching from another ARB, eprosartan can be started the day after discontinuation of the previous agent • Not a first-line ARB in Indian practice; losartan, telmisartan, and olmesartan are far more widely prescribed and available |
Secondary Indications — Adults Only (Off-label, if any)
- No well-documented or widely adopted off-label use in Indian clinical practice.
PAEDIATRIC DOSING (Specialist Only)
Primary Indications (Approved / Standard in India)
NOT AVAILABLE in India for paediatric use. Safety and efficacy of eprosartan in children and adolescents (below 18 years) have not been established.
Secondary Indications — Paediatric Doses (Off-label, if any)
NOT AVAILABLE in India. No published paediatric dosing data or Indian specialist practice supporting use in this age group.
RENAL ADJUSTMENT
| eGFR (mL/min/1.73 m²) | Recommendation |
|
≥ 50
|
No dose adjustment required; standard dosing applies |
|
30–49
|
Use with caution; monitor serum creatinine and potassium within 1–2 weeks of initiation; consider starting at 400 mg daily |
|
< 30 (not on dialysis)
|
Use only under specialist supervision; increased risk of hyperkalaemia and deterioration of renal function; start at 400 mg daily if used |
|
Haemodialysis
|
Eprosartan is not significantly removed by haemodialysis (high protein binding, predominantly biliary/faecal excretion); no supplemental dose required post-dialysis; however, use with extreme caution and specialist input |
Note: Approximately 90% of eprosartan is eliminated via the biliary/faecal route; renal excretion accounts for only ~7%. Drug accumulation with renal impairment is modest, but the haemodynamic effects of RAAS blockade on glomerular filtration remain the primary concern.
HEPATIC ADJUSTMENT
| Child-Pugh Class | Recommendation |
|
A (Mild)
|
No dose adjustment required |
|
B (Moderate)
|
Use with caution; consider initiating at 400 mg daily; monitor liver function |
|
C (Severe)
|
Avoid use; no adequate safety data available in severe hepatic impairment |
CONTRAINDICATIONS
- Known hypersensitivity to eprosartan or any excipient in the formulation
- Second and third trimesters of pregnancy
- Severe hepatic impairment (Child-Pugh C)
- Bilateral renal artery stenosis or stenosis in a solitary functioning kidney
- Concomitant use with aliskiren in patients with diabetes mellitus or in patients with renal impairment (eGFR < 60 mL/min/1.73 m²)
CAUTIONS
- Volume- or salt-depleted patients (risk of symptomatic first-dose hypotension; correct dehydration before starting)
- Unilateral renal artery stenosis (monitor renal function closely)
- Pre-existing renal impairment (eGFR < 50 mL/min/1.73 m²)
- Hyperkalaemia or concurrent use of potassium-elevating agents
- Aortic or mitral valve stenosis, hypertrophic obstructive cardiomyopathy
- History of angioedema (including prior angioedema with ACE inhibitors; cross-reactivity is rare with ARBs but reported)
- Patients with primary hyperaldosteronism (generally poor response to RAAS blockade)
- Concomitant use with an ACE inhibitor (dual RAAS blockade increases risk of hypotension, hyperkalaemia, and renal impairment — avoid unless under strict specialist supervision)
PREGNANCY
| Parameter | Detail |
|
Overall safety
|
Contraindicated in the second and third trimesters; exposure during this period is associated with fetal renal dysgenesis, oligohydramnios, skull ossification defects, and neonatal death |
|
First trimester
|
Should be avoided; if inadvertently used, discontinue as soon as pregnancy is confirmed and switch to a safer alternative |
|
Preferred alternatives in Indian obstetric practice
|
Methyldopa (first line); labetalol; nifedipine extended-release |
|
When it may be used
|
Should not be used at any stage of pregnancy |
|
Monitoring if inadvertently exposed
|
Serial ultrasonography for amniotic fluid volume, fetal renal function, and fetal growth; neonatal assessment for hypotension, oliguria, and hyperkalaemia |
LACTATION
| Parameter | Detail |
|
Compatibility with breastfeeding
|
Not recommended; it is unknown whether eprosartan is excreted in human breast milk (it is excreted in the milk of lactating rats) |
|
Expected drug levels in milk
|
Unknown in humans |
|
Preferred alternatives
|
Labetalol, nifedipine, or enalapril (all have more established breastfeeding safety data) |
|
Monitoring in infant
|
If exposure occurs, monitor infant for hypotension (lethargy, poor feeding), reduced urine output, and poor weight gain |
ELDERLY
- Recommended starting dose: 400 mg once daily
- Titration: Increase gradually over 2–4 weeks based on blood pressure response and tolerability
- Extra risks: Higher susceptibility to first-dose hypotension (especially if volume-depleted or on concomitant diuretics); age-related decline in renal reserve increases risk of deterioration of renal function; monitor serum creatinine, potassium, and blood pressure more frequently than in younger adults
- General note: No pharmacokinetic-based dose adjustment is required by age alone, but clinical caution and a lower starting dose are prudent
MAJOR DRUG INTERACTIONS
| Interacting Drug/Class | Effect / Mechanism | Action |
|
Aliskiren (in diabetic or renally impaired patients)
|
Dual RAAS blockade → increased risk of hyperkalaemia, hypotension, and acute kidney injury | Contraindicated in combination in patients with diabetes or eGFR < 60 |
|
ACE inhibitors (e.g., enalapril, ramipril)
|
Dual RAAS blockade → same risks as above | Avoid concurrent use; if unavoidable, specialist supervision and close monitoring mandatory |
|
Potassium-sparing diuretics (spironolactone, eplerenone, amiloride)
|
Additive hyperkalaemia risk | Monitor serum potassium within 1 week of combination and regularly thereafter; avoid if baseline K⁺ > 5.0 mEq/L |
|
Potassium supplements
|
Additive hyperkalaemia risk | Use only if documented hypokalaemia; monitor potassium closely |
|
Lithium
|
ARBs reduce lithium renal clearance → increased serum lithium levels and toxicity risk | Monitor lithium levels frequently if combination is unavoidable; consider alternative antihypertensive |
|
NSAIDs (including COX-2 selective inhibitors)
|
Blunting of antihypertensive effect; increased risk of acute kidney injury and hyperkalaemia, particularly in volume-depleted or elderly patients | Avoid prolonged concurrent use; if short-term NSAID use is needed, monitor renal function and blood pressure |
MODERATE DRUG INTERACTIONS
| Interacting Drug/Class | Effect | Action |
|
Thiazide or loop diuretics
|
Enhanced hypotensive effect, especially in volume-depleted patients | Ensure adequate hydration before initiating eprosartan; monitor blood pressure after starting combination |
|
Antidiabetic agents (insulin, sulfonylureas)
|
ARBs may modestly improve insulin sensitivity; risk of hypoglycaemia when combined with antidiabetic drugs | Monitor blood glucose more frequently after initiation; dose adjustment of antidiabetic may be needed |
|
Trimethoprim / co-trimoxazole
|
Trimethoprim has potassium-sparing effect → additive hyperkalaemia risk with ARBs | Check serum potassium during concurrent use, especially in elderly or renally impaired patients |
|
Heparin (including LMWH)
|
Additive hyperkalaemia risk | Monitor potassium during concurrent use |
COMMON ADVERSE EFFECTS
- Dizziness
- Headache
- Fatigue / asthenia
- Upper respiratory tract infection (nasopharyngitis, pharyngitis)
- Myalgia or arthralgia
- Mild gastrointestinal disturbance (nausea, diarrhoea)
SERIOUS ADVERSE EFFECTS
- Angioedema: Rare; may involve face, lips, tongue, or larynx — discontinue immediately and manage airway; do not re-challenge
- Hyperkalaemia (K⁺ > 5.5 mEq/L): Particularly in patients with renal impairment or those on potassium-elevating drugs; requires dose adjustment or discontinuation
- Acute renal failure: Especially in bilateral renal artery stenosis, severe heart failure, or volume depletion; discontinue and evaluate
- Severe hypotension: Particularly first-dose in volume-depleted patients; may require intravenous fluid resuscitation
- Rhabdomyolysis: Very rare; reported in post-marketing surveillance
MONITORING REQUIREMENTS
| Timing | Parameters |
|
Baseline (before initiation)
|
Blood pressure, serum creatinine, eGFR, serum potassium, sodium; assess volume status |
|
1–2 weeks after initiation or dose change
|
Blood pressure, serum creatinine, eGFR, serum potassium |
|
Long-term (every 3–6 months for stable patients)
|
Blood pressure, renal function (creatinine, eGFR), serum electrolytes (potassium, sodium) |
|
Situational
|
Recheck renal function and potassium if intercurrent illness (diarrhoea, vomiting, fever), addition of interacting drug (NSAID, diuretic, potassium-sparing agent), or symptoms of hypotension develop |
BRANDS AVAILABLE IN INDIA
- Availability of eprosartan in India is very limited. Commonly cited brand names include Eprisan and Eprosar, but current market availability should be verified through updated CDSCO or pharmacy databases before prescribing.
- Eprosartan is not among the commonly used ARBs in India (losartan, telmisartan, olmesartan, and valsartan are far more widely available and prescribed).
PRICE RANGE (INR)
- Estimated price: approximately ₹15–25 per 400 mg tablet and ₹20–35 per 600 mg tablet (brand- and region-dependent)
- Not listed on NLEM (National List of Essential Medicines); not NPPA price-controlled
- Due to limited availability, actual market prices should be confirmed at point of purchase
- Government supply: not routinely stocked in government hospitals or CGHS/ESIC dispensaries
CLINICAL PEARLS
- Limited role in Indian practice: Eprosartan is rarely prescribed in India; telmisartan, losartan, and olmesartan are preferred ARBs due to wider availability, more extensive Indian clinical experience, and inclusion in NLEM (telmisartan, losartan).
- Unique pharmacology: Eprosartan is the only non-biphenyl, non-tetrazole ARB and additionally blocks presynaptic AT₁ receptors on sympathetic nerve terminals, potentially offering a modest sympatholytic advantage — though clinical significance of this difference is debatable.
- Predominantly biliary excretion: Over 90% eliminated via the biliary/faecal route; among ARBs, it has the least dependence on renal excretion — theoretically advantageous in mild-to-moderate renal impairment, though clinical outcomes data are limited.
- Volume status matters: Always assess and correct volume depletion before starting. First-dose hypotension is avoidable with adequate hydration and a lower starting dose.
- Never combine with ACE inhibitor + ARB + aliskiren (triple RAAS blockade): This combination has been associated with increased morbidity in clinical trials and is contraindicated.
- Counsel on angioedema: Though rare with ARBs (much rarer than with ACE inhibitors), advise patients to report any facial, lip, or tongue swelling immediately.
VERSION
RxIndia v0.2 — 01 Mar 2026
REFERENCES
- CDSCO (Central Drugs Standard Control Organisation) — product approval and scheduling data
- Indian Pharmacopoeia
- API Textbook of Medicine
- AIIMS Treatment Guidelines
- Goodman & Gilman’s The Pharmacological Basis of Therapeutics (eprosartan pharmacology and pharmacokinetics)
- Harrison’s Principles of Internal Medicine (ARB class overview)
- NLEM 2022 (for confirmation of non-inclusion)
⚖️
Clinical Responsibility
This platform is designed strictly for healthcare professionals. Data provided is synthesized from authoritative pharmacological sources and clinical registries. Do not use for consumer medical decisions. Always verify critical dosing and contraindications with official institutional protocols and peer-reviewed journals.
Content Feedback
Is this information helpful?
Help us improve our clinical database for the medical community.